Related Experiment Video
Updated: Oct 18, 2025
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Avapritinib in the Treatment of Systemic Mastocytosis: an Update
Samantha Below1, Laura C Michaelis2
1Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA.
Purpose Of Review:
Patients with systemic mastocytosis, a dangerous and rare myeloid neoplasm, have long had few therapies available to them and, historically, rarely achieved from significant disease control. However, research and translational developments over the last decade have led to promising new options for disease management. In this review, we briefly outline the history of treatment for systemic mastocytosis and subsequently focus on the clinical development and potential applications of avapritinib (previously known as BLU-285), a potent and selective oral inhibitor of the tyrosine kinase most commonly mutated in this condition.
Recent Findings:
Phase I data and recent phase II data have demonstrated both safety and efficacy of this agent used as monotherapy, even in patients who have progressed on other targeted therapy. Studies to date have focused on patients with the most aggressive disease, but new trials in indolent mastocytosis are accruing currently. Over the next several years, one may anticipate finalized, peer-reviewed, and formally published data for this agent in both advanced systemic and indolent mastocytosis. Evidence from these early studies will also likely highlight where more research is needed.
Insights
Avapritinib offers a promising new targeted therapy for systemic mastocytosis, a rare myeloid neoplasm. Clinical trials show safety and efficacy, even in patients resistant to other treatments, offering hope for better disease control.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Systemic mastocytosis is a rare myeloid neoplasm with limited therapeutic options.
- Historically, significant disease control has been challenging for patients.
- Recent advancements have introduced promising new management strategies.
Purpose of the Study:
- To review the historical treatment landscape of systemic mastocytosis.
- To focus on the clinical development of avapritinib (BLU-285).
- To explore the potential applications of avapritinib in managing systemic mastocytosis.
Main Methods:
- Review of historical treatment data for systemic mastocytosis.
- Analysis of clinical development data for avapritinib.
- Evaluation of safety and efficacy data from Phase I and II trials.
Main Results:
- Avapritinib demonstrates safety and efficacy as monotherapy.
- The drug shows effectiveness even in patients who progressed on other targeted therapies.
- Ongoing trials are evaluating avapritinib in indolent mastocytosis.
Conclusions:
- Avapritinib represents a significant advancement in systemic mastocytosis treatment.
- Further data from ongoing trials will clarify its role in both advanced and indolent forms.
- Future research will identify areas needing further investigation for optimal patient outcomes.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...